Sareum Holdings plc (LON:SAR – Get Free Report)’s stock price traded up 12% on Friday . The company traded as high as GBX 23.74 and last traded at GBX 23.74. 655,216 shares changed hands during trading, an increase of 193% from the average session volume of 223,444 shares. The stock had previously closed at GBX 21.20.
Sareum Stock Up 12.0%
The business has a 50-day simple moving average of GBX 22.46 and a 200-day simple moving average of GBX 19.47. The company has a market cap of £32.90 million, a PE ratio of -6.09 and a beta of -1.08.
Sareum Company Profile
Sareum is a specialist drug development company delivering targeted small molecule therapeutics to improve the treatment of cancer and autoimmune diseases. The Company aims to generate value through licensing its candidates to international pharmaceutical and biotechnology companies at the preclinical or early clinical trials stage.
Sareum is advancing internal programmes focused on distinct dual tyrosine kinase 2 (TYK2) / Janus kinase 1 (JAK1) inhibitors through preclinical development as therapies for autoimmune diseases, including the ‘cytokine storm’ immune system overreaction to Covid-19 and other viral infections, (SDC-1801) and cancer immunotherapy (SDC-1802).
Sareum also has an economic interest in SRA737, a clinical-stage oral, selective Checkpoint kinase 1 (Chk1) inhibitor that targets cancer cell replication and DNA damage repair mechanisms.
Further Reading
- Five stocks we like better than Sareum
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for Sareum Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sareum and related companies with MarketBeat.com's FREE daily email newsletter.
